Alkermes plc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
Business Address CONNAUGHT HOUSE, DUBLIN 4, L2, 00000
Mailing Address CONNAUGHT HOUSE, DUBLIN 4, L2, 00000
Phone 00-353-1-772-8000
Fiscal Year End 1231
EIN 981007018
Financial Overview
FY2024
$367.07M
Net Income
$933.54M
Total Liabilities
$1.46B
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
Insider Trading
STRONG SELL 2 insiders
8 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.